SEREVENT by GSK is laba. Approved for asthma, the prevention of bronchospasm only, older with reversible obstructive airway disease and 3 more indications. First approved in 1994.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
SEREVENT (salmeterol) is a long-acting beta-2 agonist (LABA) inhaled as a metered aerosol for chronic obstructive pulmonary disease. It works by stimulating beta-2 adrenergic receptors in bronchial smooth muscle, increasing cyclic AMP and causing bronchodilation while inhibiting mast cell mediator release. Salmeterol is at least 50 times more selective for beta-2 adrenergic receptors than albuterol, providing sustained airway relaxation.
As a product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team will focus on lifecycle extension and defending market position against newer fixed-dose combinations.
LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are…
Worked on SEREVENT at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography
ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.
Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
SEREVENT offers limited career momentum given its approaching LOE and minimal linked job openings; however, roles focusing on market defense, competitive positioning, and commercial strategy remain relevant. Working on this mature asset builds expertise in late-lifecycle management and defending blockbuster-class products against generic and branded competition.